Effect of Methylphenidate on State Anxiety in Children With ADHD-A Single Dose, Placebo Controlled, Crossover Study

Maya Kritchman, May Koubi, Aviva Mimouni Bloch, Yuval Bloch, Maya Kritchman, May Koubi, Aviva Mimouni Bloch, Yuval Bloch

Abstract

Introduction: Non-adherence to efficacious pharmacotherapy is a major obstacle in the treatment of children suffering from attention deficit hyperactive disorder (ADHD). Some hold the position that pharmacotherapy induces anxiety, and that this is one of the reasons for this non-adherence. Previous studies have pointed to the opposite, a moderating effect of methylphenidate (MPH) on state anxiety in patients with ADHD. This has been shown in continuous treatment in children, but not on a single dose. We hypothesized that a single dose might have a different effect. Method: Twenty children with ADHD were given single doses of MPH in a randomized, controlled, crossover, double blind study. State anxiety using The Spielberger State-Trait Anxiety Inventory (STAI) and a continuous performance test were assessed. Results: As a group, no change was detected in state anxiety with MPH or placebo. However, children who were given MPH during the first session as opposed to those who received placebo first, demonstrated deterioration in baseline state anxiety in the second session [t (2.485), p < 0.05]. Conclusion: Our findings show a possible delayed anxiety-provoking effect of a single dose of MPH. This may be relevant to the understanding of difficulties in adherence with MPH treatment in children with ADHD. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT01798459.

Keywords: ADHD; attention-deficit hyperactivity disorder; methylphenidate; pharmacotherapy; state anxiety.

References

    1. Atkinson M., Hollis C. (2010). NICE guideline: attention deficit hyperactivity disorder. Arch. Dis. Child. Educ. Pract. Ed. 95, 24–27. 10.1136/adc.2009.175943
    1. Bloch Y., Aviram S., Segev A., Nitzan U., Levkovitz Y., Braw Y., et al. . (2017). Methylphenidate reduces state anxiety during a continuous performance test that distinguishes adult ADHD patients from controls. J. Atten. Disord. 21, 46–51. 10.1177/1087054712474949
    1. Bussing R., Fernandez M., Harwood M., Wei H, Garvan C. W., Eyberg S. M., et al. . (2008). Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 15, 317–328. 10.1177/1073191107313888
    1. Chang Z., Quinn P. D., Hur K., Gibbons R. D., Sjölander A., Larsson H., et al. . (2017). Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 74, 597–603. 10.1001/jamapsychiatry.2017.0659
    1. Coughlin C. G., Cohen S. C., Mulqueen J. M., Ferracioli-Oda E., Stuckelman Z. D., Bloch M. H. (2015). Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 25, 611–617. 10.1089/cap.2015.0075
    1. De Luca C. R., Wood S. J., Anderson V., Buchanan J. A., Proffitt T. M., Mahony K., et al. . (2003). Normative data from the CANTAB. I: development of executive function over the lifespan. J. Clin. Exp. Neuropsychol. 25, 242–254. 10.1076/jcen.25.2.242.13639
    1. Erskine H. E., Norman R. E., Ferrari A. J., Chan G. C., Copeland W. E., Whiteford H. A., et al. . (2016). Long-term outcomes of attention-deficit/hyperactivity disorder and conduct disorder: a systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 55, 841–850. 10.1016/j.jaac.2016.06.016
    1. Frank E., Ozon C., Nair V., Othee K. (2015). Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J. Clin. Psychiatry 76, e1459–e1468. 10.4088/JCP.14r09478
    1. Fredriksen M., Peleikis D. E. (2016). Long-term pharmacotherapy of adults with attention deficit hyperactivity disorder: a literature review and clinical study. Basic Clin. Pharmacol. Toxicol. 118, 23–31. 10.1111/bcpt.12477
    1. Group M. C. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry 56, 1073–1086. 10.1001/archpsyc.56.12.1073
    1. Hall C. L., Guo B., Valentine A. Z., Groom M. J., Daley D., Sayal K., et al. (2019). The validity of the SNAP-IV in children displaying ADHD symptoms. Assessment 16:1073191119842255 10.1177/1073191119842255
    1. Kovshoff H., Banaschewski T., Buitelaar J. K., Carucci S., Coghill D., Danckaerts M., et al. . (2016). Reports of perceived adverse events of stimulant medication on cognition, motivation, and mood: qualitative investigation and the generation of items for the medication and cognition rating scale. J. Child Adolesc. Psychopharmacol. 26, 537–547. 10.1089/cap.2015.0218
    1. Larson K., Russ S. A., Kahn R. S., Halfon N. (2011). Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 127, 462–470. 10.1542/peds.2010-0165
    1. Lichtenstein P., Halldner L., Zetterqvist J., Sjölander A., Serlachius E., Fazel S., et al. . (2012). Medication for attention deficit-hyperactivity disorder and criminality. N. Engl. J. Med. 367, 2006–2014. 10.1056/NEJMoa1203241
    1. Oei T. P., Evans L., Crook G. M. (1990). Utility and validity of the STAI with anxiety disorder patients. Br. J. Clin. Psychol. 29(Pt 4), 429–432. 10.1111/j.2044-8260.1990.tb00906.x
    1. Okun A., Stein R. E., Bauman L. J., Silver E. (1996). Content validity of the psychiatric symptom index, CES-depression scale, and state-trait anxiety inventory from the perspective of DSM-IV. Psychol. Rep. 79(3 Pt 1), 1059–1069. 10.2466/pr0.1996.79.3.1059
    1. Pozzi M., Carnovale C., Peeters G., Gentili M., Antoniazzi S., Radice S., et al. . (2018). Adverse drug events related to mood and emotion inpaediatric patients treated for ADHD: a meta-analysis. J. Affect. Disord. 238, 161–178. 10.1016/j.jad.2018.05.021
    1. Rossi V., Pourtois G. (2012). Transient state-dependent fluctuations in anxiety measured using STAI, POMS, PANAS, or VAS: a comparative review. Anxiety Stress Coping 25, 603–645. 10.1080/10615806.2011.582948
    1. Sayal K., Prasad V., Daley D., Ford T., Coghill D. (2018). ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry 5, 175–186. 10.1016/S2215-0366(17)30167-0
    1. Sciberras E., Lycett K., Efron D., Mensah F., Gerner B., Hiscock H. (2014). Anxiety in children with attention-deficit/hyperactivity disorder. Pediatrics 133, 801–808. 10.1542/peds.2013-3686
    1. Seixas M., Weiss M., Müller U. (2012). Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J. Psychopharmacol. 26, 753–765. 10.1177/0269881111412095
    1. Sheehan D. V., Sheehan K. H., Shytle R. D., Janavs J., Bannon Y., Rogers J. E., et al. . (2010). Reliability and validity of the mini international neuropsychiatric interview for children and adolescents (MINI-KID). J. Clin. Psychiatry 71, 313–326. 10.4088/JCP.09m05305whi
    1. Spielberger C. D., Gorsuch R. L., Lushene R. E. (1970). Manual for the State Trait Anxiety Inventory (Self-Evaluation Questionnaire). Palo Alto, CA: Consulting Psychological Press.
    1. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement Management. Wolraich M., Brownm L, Brown R. T., DuPaul. G., et al. . (2011). ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128, 1007–1022. 10.1542/peds.2011-2654
    1. Teichman Y., Melink C. (1984). Hebrew Manual for the STAI, STAIC, 2nd Edn. Ramot: Ramat Aviv.
    1. Wang L. J., Yang K. C., Lee S. Y., Yang C., Huang T. S., Lee T. L., et al. . (2016). Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS ONE 11:e0161061. 10.1371/journal.pone.0161061
    1. Zohar A. H., Bruno R. (1997). Normative and pathological obsessive-compulsive behavior and ideation in childhood: a question of timing. J. Child Psychol. Psychiatry 38, 993–999. 10.1111/j.1469-7610.1997.tb01616.x

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel